Log in to save to my catalogue

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7953461

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

About this item

Full title

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2021-04, Vol.384 (16), p.1491-1502

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

The interleukin-6 receptor blockers tocilizumab and sarilumab were tested against standard care in a randomized trial involving patients newly admitted to the intensive care unit and requiring respiratory or blood-pressure support. The median number of organ support–free days was 10 with tocilizumab, 11 with sarilumab, and 0 with standard care.

Alternative Titles

Full title

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7953461

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7953461

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2100433

How to access this item